Cargando…
Efficacy of MEK inhibition in a K-Ras-driven cholangiocarcinoma preclinical model
Intrahepatic cholangiocarcinoma (iCCA) is a deadly malignancy with limited treatment options. Gain-of-function mutations in K-Ras is a very frequent alteration, occurring in ~15 to 25% of human iCCA patients. Here, we established a new iCCA model by expressing activated forms of Notch1 (NICD) and K-...
Autores principales: | Dong, Mingjie, Liu, Xianqiong, Evert, Katja, Utpatel, Kirsten, Peters, Michele, Zhang, Shanshan, Xu, Zhong, Che, Li, Cigliano, Antonio, Ribback, Silvia, Dombrowski, Frank, Cossu, Antonio, Gordan, John, Calvisi, Diego F., Evert, Matthias, Liu, Yan, Chen, Xin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833851/ https://www.ncbi.nlm.nih.gov/pubmed/29348467 http://dx.doi.org/10.1038/s41419-017-0183-4 |
Ejemplares similares
-
Inhibition of MELK Protooncogene as an Innovative Treatment for Intrahepatic Cholangiocarcinoma
por: Cigliano, Antonio, et al.
Publicado: (2019) -
MEK inhibition suppresses K-Ras wild-type cholangiocarcinoma in vitro and in vivo via inhibiting cell proliferation and modulating tumor microenvironment
por: Wang, Pan, et al.
Publicado: (2019) -
SKP2 cooperates with N-Ras or AKT to induce liver tumor development in mice
por: Delogu, Salvatore, et al.
Publicado: (2014) -
Early Subcellular Hepatocellular Alterations in Mice Post Hydrodynamic Transfection: An Explorative Study
por: Yasser, Mohd, et al.
Publicado: (2023) -
The Hippo pathway effector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human disease
por: Cigliano, Antonio, et al.
Publicado: (2022)